Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.37 |
| ▸ | NQO2 | P16083 | 6/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | S100B | P04271 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390530 | 0.79 | PDE3B (0.33) | PDE3BPDE3AALDH1A1MAPTPDE4B | |
| SCHEMBL25192441 | 0.78 | CYP1A2 (0.37) | PDE3BPDE3ACYP19A1NQO2HDAC4 | |
| SCHEMBL21921254 | 0.78 | ATAD2 (0.36) | PDE3BPDE3AS100BALDH1A1GAA | |
| SCHEMBL22016779 | 0.77 | KDM4E (0.40) | PDE3BPDE3ACRHR1ALDH1A1GAA | |
| SCHEMBL22037773 | 0.77 | PDE3B (0.43) | PDE3BPDE3ACYP19A1NQO2S100B | |
| SCHEMBL25186771 | 0.77 | PDE3B (0.35) | PDE3BPDE3AHDAC4HDAC8S100B | |
| SCHEMBL25181919 | 0.76 | L3MBTL1 (0.42) | PDE3BPDE3AHDAC4HDAC8ALDH1A1 | |
| SCHEMBL20280294 | 0.76 | CRHR1 (0.38) | PDE3BPDE3ACRHR1ALDH1A1GAA | |
| SCHEMBL21955358 | 0.74 | PDE3B (0.42) | PDE3BPDE3ACYP19A1NQO2S100B | |
| SCHEMBL20844006 | 0.73 | POLB (0.35) | PDE3BPDE3ACYP19A1NQO2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | PDE3B 87/4885PDE3A 266/4885CYP19A1 1159/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | PDE3B 335/4885PDE3A 764/4885CYP19A1 4552/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | PDE3B 87/4885PDE3A 266/4885CYP19A1 1159/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | PDE3B 335/4885PDE3A 764/4885CYP19A1 4552/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | PDE3B 248/4885PDE3A 912/4885CYP19A1 3731/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | PDE3B 87/4885PDE3A 266/4885CYP19A1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.